Paul Grint is the president of Cerexa. Grint has significant experience in anti-infective, oncology, and inflammation research and clinical development in both domestic and international markets. Prior to joining Cerexa, Grint was a senior vice president at Forest Research Institute, Inc., a subsidiary of Forest Laboratories, Inc. Prior to joining Forest Laboratories, he was the chief medical officer at Kalypsys Inc., a biopharmaceutical company based in San Diego, California. Before joining Kalypsys, Grint served as senior vice president and chief medical officer of Zephyr Sciences, and has previously held similar positions at Pfizer La Jolla, IDEC Pharmaceuticals, and Schering-Plough Research Institute (SPRI). Grint received his bachelor's degree from St. Mary's Hospital, London, and his medical degree at University of London, St. Bartholomew's Hospital Medical College. He is a Fellow of the Royal College of Pathologists.